Members of the EGF family of growth factors play critical roles during normal and neoplastic breast development. EGF family member HRGa is the only HRG1 isoform expressed in the mouse mammary gland and our previous experiments suggest that HRG1 has a unique role in mammary development. To determine the function of HRGa activity during mouse mammary gland development, we generated a HRGa-deficient mouse strain. Unlike mice with HRG1 or isoform specific HRGb gene deletions, HRGa-null mice survive to adulthood. HRGadeficient mice display pronounced defects in mammary gland lobuloalveolar development at 17 days of pregnancy and 3 days post-partum. Terminal and lateral ductal alveoli were condensed and alveolar outgrowth during pregnancy was severely impaired. A dramatic reduction in b-casein expression accompanied defective alveolar development in the HRGa-null mice, as determined by in situ hybridization and Northern blot analysis of HRGadeficient mammary glands at 3 days post-partum. Expression of the milk-protein genes WAP and alactalbumin was not adversely affected. In situ incorporation of BrdU demonstrated that epithelial proliferation was significantly curtailed in mammary glands of HRGadeficient mice at 17 days post-coitus and 3 days postpartum. These results demonstrate that HRGa is an important mammary gland mitogen regulating alveolar development and lactogenesis.
Introduction
Normal breast development is mediated by the combined activities of systemic hormones and locally synthesized growth factors. The influence of systemic hormones on mammary gland development may be governed indirectly through the stimulation of locally synthesized growth factors. One suggestion is that mammary gland expressed growth factors activate epithelial cell surface receptors and in this way have a direct impact on epithelial proliferation, differentiation, and programmed cell death (reviewed in: Ronnov-Jessen et al., 1996; Sakakura, 1991) .
Experimental evidence suggests that members of the EGF family represent an important group of growth factors expressed in the developing mammary gland. Generation of various double and triple growth factor null mice revealed an essential role for amphiregulin (AR) in ductal morphogenesis and important functions for EGF and TGFa during lactogenesis (Luetteke et al., 1999) . Similarly, substantial evidence suggests that the ErbB3 and ErbB4 ligand, HRG1, regulates epithelial proliferation and differentiation during lobuloalveolar development and lactogenesis. We examined the effects of HRG1 stimulation on mammary epithelial morphogenesis in mammary gland organ cultures. These experiments clearly indicate that HRG1 enhances lobuloalveolar development and stimulates the accumulation of secretory alveoli (Yang et al., 1995) . In addition, we have previously demonstrated that mammary implants containing HRG1 induce ductal proliferation and epithelial differentiation into secretory lobuloalveolar structures (Jones et al., 1996) . Although expression of two major splice isoforms of HRG1 have been identified in several tissues, only the alpha isoform is expressed in the mammary gland (Yang et al., 1995) . Moreover, mammary gland expression of HRGa peaks at midpregnancy (Yang et al., 1995) , corroborating a role for HRGa in lobuloalveolar development.
The biological effects of HRG1 on mammary epithelial cells in vitro also supports a dual role for HRG1 in epithelial proliferation and secretory differentiation. HRG1 has been reported to induce proliferation of human breast cancer cell lines Holmes et al., 1992; Lupu et al., 1992) as well as the murine mammary epithelial cell line HC11 (Marte et al., 1995) . Most recently, Slamon and co-workers employed a variety of growth response assays to evaluate the growth stimulatory effects of HRG1 on several breast cancer cell lines and normal mammary epithelial cells. Their results also support a mitogenic role for HRG1 in human breast epithelial cells (Aguilar et al., 1999) . In contrast, HRG1 induces functional differentiation of the human breast cancer cell lines AU565 (Chen et al., 1996; Peles et al., 1992) , SkBr-3 (Le et al., 2000) , and MCF-7 (Chen et al., 1996) . Similarly, matri-gel collagen matrix cultures of the EpH4 mammary epithelial cell line and human breast tumor explants undergo functional differentiation, forming alveoli-like structures and expressing the milk protein b-casein, when treated with HRG1 (Niemann et al., 1998) .
Despite convincing evidence supporting HRG1's active role in mammary epithelial mitogenesis and differentiation, the exact function of HRG1 signaling in the normal breast has remained elusive. Mice with genetic disruptions of both HRG1 alleles die in utero at E10.5 , prior to the earliest stages of embryonic mammary crest formation (reviewed in Topper and Freeman, 1980) . To overcome the embryonic lethality caused by deletion of both the alpha and beta isoforms of HRG1, we selectively deleted the HRG1 isoform known to be expressed in the mouse breast, HRGa. In contrast to HRG1-null mice, the HRGa mutant mice survive to adulthood, therefore providing an in vivo model to analyse HRGa function during mammary gland development. The HRGa-null mice exhibited severe defects in lobuloalveolar development and function which were attributed to abrogated proliferation of lumenal mammary epithelial cells during pregnancy and lactation. These experiments represent the first description of HRGa activity in vivo and demonstrate a functional role for HRGa as an important mammary epithelial mitogen.
Results

Generation of HRGa-null mice
Two independently derived ES cell clones that carry the mutant HRGa allele were used to establish a mouse strain by standard techniques. Mice that carry the heterozygous or homozygous HRGa mutation showed no overt phenotype. To verify the presence of the mutation in such mice, RT -PCR experiments were performed on RNA isolated from wild type, heterozygous or homozygous E12 embryos. The primers amplified mRNA sequences encoded by exons 6 and 7 (a-isoform) or 6 and 8 (b-isoform). The PCR products were subjected to cleavage by EcoRI, which allowed the identification of PCR products that derive from mutant mRNA and that carry, in addition to the inserted mutation, the novel EcoRI restriction site. We observed in heterozygous or homozygous mutant mice a reproducible decrease in the amount of PCR product from the mutant allele (Figure 1d ). This appears to reflect a destabilization of the mutant mRNA by nonsense-mediated decay, a mechanism used for the elimination of mRNAs that carry a premature termination codon (Culbertson, 1999; Hentze and Kulozik, 1999) .
HRGa functions in lobuloalveolar development
To evaluate the role of HRGa-signaling during mouse mammary gland development, we prepared wholemounts and histological sections of mammary glands from homozygous null and wild type littermates at 5, 7, 10 and 12 weeks of nulliparous development; 12, and daily between 15 and 19 days of pregnancy (P); 1 to 3, 6, 9, 12, 14, and 15 days following parturition (L); and 2 and 4 days after weaning. Initially, at least three (a) The structure of the wild type HRG1 locus is shown at the top. The mutant HRGa allele was generated in two steps. In the first step, the targeting vector with the desired sequence alterations in exon 7 (indicated in red, see also b) and a neo r cassette flanked by loxP sites was introduced by homologous recombination into ES cells; this generated the HRG aneo allele. In a second step, the neomycin resistance cassette was removed by transient transfection of a Cre-expression plasmid (pIC-Cre, Torres and Kuhn, 1997), producing the mutant HRGa allele. Exons in the HRG1 gene are shown by black boxes and numbered; loxP sites are indicated by blue arrows. Two EcoRI sites present in the wild type allele are indicated by black arrows. In the mutant allele, three additional EcoRI sites were introduced and are indicated by red arrows; they are located in the mutant exon 7 (see also b) and at the borders of two loxP sites. The probes used for Southern hybridization in (c) are indicated, as are the sizes and positions of expected fragments generated by EcoRI digestion of genomic DNA containing wild type and HRGa mutant alleles. (b) Partial sequences of wild type (Wt) and mutant (Mu) HRGa alleles; two point mutations (red) were introduced into the mutant exon 7; they introduce a stop codon into the sequence encoding the a-isoform-specific EGF-like domain, and generate a novel EcoRI site. (c) Southern hybridization of genomic DNA from control, heterozygous and homozygous HRGa mutant mice after EcoRI digestion using as probe the fragment indicated in (a). (d) RT -PCR analysis on total RNA from E12 mice that carry the indicated genotypes; primers used for the PCR amplification hybridize to exon 8 (b-specific) or 7 (a-specific) and exon 6 (shared by a-and b-isoforms). The amplified product was digested with EcoRI where indicated, to detect the novel EcoRI restriction site present in transcripts of the mutant HRGa allele HRGa-null and three wild type mice were analysed at each time point.
Mammary gland development in the HRGa-deficient mice progressed normally within nulliparous animals. During pregnancy, accumulation of ductal alveoli was evident in mammary glands from wild type mice at P12.5 (the earliest pregnancy time point examined; Figure 2a) . A slight decrease in alveolar development was observed, however, in HRGa-null mice at P12.5 ( Figure 2b ) and this defect in lobuloalveolar development was exaggerated by P17 ( Figure 2d ). In contrast, extensive alveolar proliferation was evident in control mammary glands at P17 (Figure 2c ). Large alveolar clusters were easily detected in hematoxylin and eosin stained paraffin sections from wild type mammary glands at P17 (Figure 2e , arrow). The lumens of wild type alveoli were distended due to accumulation of lipids and early lactation products (Figure 2e , arrowhead). Development of lobuloalveolar clusters in HRGa-deficient mice was less extensive. Each lobuloalveolar cluster consisted of fewer alveoli (Figure 2f , arrow) and the alveoli remained condensed suggesting a defect in functional maturation (Figure 2f, arrowhead) . This phenotype was observed in each of seven HRGa-null mice analysed at P17 and none of the five control mice analysed. Despite defects in alveolar development observed between P12.5 and P17, mammary gland development in HRGa-deficient mice appeared to progress normally during the late stages of pregnancy.
During lactation, direct comparison of HRGadeficient and wild type mammary gland development was performed between siblings maintaining litters of eight to 10 mice. At parturition (L1), HRGa-null mammary glands partially recovered from defects accumulated during pregnancy (Figure 3b ) and the extent of lobuloalveolar development appeared similar to wild type mammary glands at L1 (Figure 3a) . A majority of the alveoli in HRGa-deficient mammary glands at L1, however, appeared excessively distended Figure  3e, arrowhead) . In contrast, lobuloalveolar accumulation was impaired in HRGa-null mice resulting in a fatpad that was sparsely populated with abnormally distended alveoli (Figure 3d, arrow) . Although intracellular lipids were apparent within lumenal epithelium, indicating secretory activity, the majority of these cells appeared flat (Figure 3f , arrowhead) when compared to the cuboidal epithelium observed in wild type alveoli. The phenotype at L3 was observed in each of eight HRGa-null mice analysed and none of 11 wild type mice analysed. By L6 mammary glands from HRGanull mice (Figure 3h ) appeared similar to wild type mammary glands at the same developmental stage (Figure 3g ). In summary, impaired lobuloalveolar development was transient and observed in HRGadeficient mammary glands at two temporally and functionally distinct stages of development, namely mid-pregnancy (P12.5 -17) and early post-partum (L3).
Despite the transient disruption of lobuloalveolar development, HRGa-deficient dams were able to lactate and support their litters without apparent detrimental effects on sucklings or weanlings (data not shown). Indeed, daily measurement of suckling weights from three wild type and three HRGa-null dams with matched litter sizes failed to reveal differences in growth rates or weights of pups from 3 -21 days of age (data not shown).
Mammary glands from HRGa-null mice have impaired milk-gene expression
To determine if lactation was affected in HRGadeficient mice, we performed in situ hybridization and Northern blot analysis of lactating mammary glands from wild type and HRGa-null mice. Cellular populations in wild type ( Figure 4a ) and HRGa-null ( Figure  4c ) mammary glands at L3 were identified in hematoxylin and eosin stained serial sections representing the same alveolar clusters hybridized with a b-casein antisense probe (Figure 4b,d, respectively) . In situ hybridization of wild type mammary glands at L3 revealed high levels of b-casein transcripts localized to alveolar epithelium (Figure 4b ). In contrst, b-casein expression was dramatically reduced within alveolar epithelium of HRGa-deficient mammary glands at L3 (Figure 4d) . In situ hybridization analysis failed to reveal obvious differences in the levels of WAP or a-lactalbumin expression (data not shown). The defect in b-casein expression was confirmed by Northern blot analysis of total RNA isolated from wild type and HRGa-null mammary glands at L3 (Figure 4e) . b-casein expression was easily detected in mammary gland RNA from wild type mice (Figure 4e, lane 1) ; however, a dramatically lower level of b-casein expression was observed in RNA from two independent HRGa-deficient mice (Figure 4e , lanes 2 and 3). Equivalent levels of WAP expression were detected in RNA from wild type and HRGa-null mammary glands (Figure 4e) . In contrast, a-lactalbumin expression levels increased in the absence of HRGa. Enhanced a-lactalbumin expression observed in HRGadeficient mammary glands may represent a mechanism to compensate for impaired b-casein expression. As a control for RNA loading, GAPDH expression was assessed (Figure 4e ). Reduced b-casein expression had no detectable consequence on sucklings daily growth rates or pups weaned from HRGa-null mothers (data not shown).
Replication of alveolar epithelium is abrogated in HRGa-null mice
Increased mammary epithelial replication during pregnancy and early post-partum (Traurig, 1967a,b) correlates with the mammary gland phenotype observed in HRGa-deficient mice. Bromodeoxyuridine (BrdU) incorporation in situ was used to determine if the defect in lobuloalveolar development observed in HRGa-null mammary glands at P17 and L3 was a 1) and HRGa-null (e lanes 2 and 3) mice at L3. The same blot was probed sequentially with the indicated genes. Lanes 2 and 3 represent mammary gland RNAs from two independent HRGa-null mice result of impaired epithelial proliferation at these stages. Nulliparous female mice between 6 and 7 weeks old were included in these experiments as positive controls. HRGa expression is not detected in the nulliparous mammary gland (Yang et al., 1995) and ductal expansion throughout the nulliparous mammary fatpad of HRGa-deficient mice progressed normally (data not shown). Equivalent levels of epithelial cell replication in terminal end-buds of nulliparous mammary glands at early puberty were detected in both wild type and HRGa-deficient mice (data not shown and Figure 5c ). As predicted, alveolar clusters in mammary glands of wild type mice at P17 (Figure 5a ,c) and L3 (data not shown and Figure 5c ) contained a high percentage of epithelial cells with BrdU-labeled nuclei. In striking contrast, BrdU-labeled nuclei were only rarely detected in mammary glands of HRGa-null mice at P17 (Figure 5b arrowhead and Figure 5c ) and L3 (data not shown and Figure 5c ). Figure 5c ) and support an important mitogenic role for HRGa-signaling within mammary glands of pregnant and lactating mice.
Discussion
The EGF family of growth factors display important functions during several stages of mammopoiesis. In vitro experiments and limited in vivo studies suggest that the ErbB3 and ErbB4 ligand, HRG1, contributes to both epithelial proliferation and differentiation during mammary gland lobuloalveolar development. Functional deletion of HRG1 results in an embryonic lethal phenotype precluding the use of HRGa-null mice for the analysis of HRG1-regulated developmental events within the mammary gland. In this communication, we circumvented the embryonic lethal phenotype associated with a HRG1 genetic knockout by selectively deleting the HRG1 isoform expressed in the mouse mammary gland, HRGa (Yang et al., 1995) . Interestingly, HRGa-deficient mice survive to adulthood. In contrast, HRGb-null mice display reduced survival, but some make it to birth and die post-natally. These latter results suggest that myocardial defects are partially rescued in HRGb-deficient mice (Li Li and C Birchmeier, unpublished observations). Here we demonstrate that HRGa is a potent breast mitogen with an important role in mammary gland development and lactogenesis.
Mammary gland development during pregnancy is characterized by the proliferation of lumenal epithelium and functional maturation of ductal lactogenic units or lobuloalveoli. At parturition, lactogenesis is initiated and the accumulation of lactation products results in alveolar distention. Mice lacking HRGa fail to accumulate lobuloalveoli during pregnancy, a phenotype most apparent at 17 days post-coitus. Despite obvious metabolic and secretory activity of HRGa-null alveolar epithelium, the lobuloalveoli remained condensed. Defective alveolar development was also detected in HRGa-deficient mice at 3 days post-partum; the final stage of pronounced mammary epithelial proliferation. Mammary gland expression profiles of HRGa corroborate a critical role for HRGa signaling in lobuloalveolar proliferation during pregnancy and early post-partum. HRGa expression within the mammary gland peaks at mid-to late pregnancy with a diminution in HRGa expression levels during the progression of lactation (Yang et al., 1995) , until 6 to 9 days post-partum when HRGa expression is undetectable by RT -PCR analysis (F Jones, unpublished observations and Schroeder and Lee, 1998) .
The final stages of mammary gland development culminate at parturition when functional differentiation of alveolar epithelium results in milk gene expression and lactation. Although the accumulation of lipid droplets and, thus the initiation of lactation, was evident in alveoli of pregnant HRGa-null mice, these mice failed to express the normal profile of milk genes Figure 5 Identification of replicating mammary epithelium in situ. Wild type (a) and HRGa-null (b) mice at P17 were injected with BrdU cell labeling reagent 2 h prior to sacrifice. A portion of the number four inguinal mammary gland was excised, fixed in paraformaldehyde, and paraffin embedded. Sections were processed for BrdU immunohistochemistry as described in Materials and methods. A rare BrdU labeled nuclei in HRGa-null mice at P17 (b) is indicated by an arrowhead. A histogram representation (c) of the percentage of BrdU-labeled nuclei within wild type (solid bars) and HRGa-null (open bars) mammary glands was determined at 6 -7 wks, P17 (17d pc), and L3 (3d pp). Data represents the mean and standard deviation of 1000 epithelial nuclei from five different control and experimental mice at each developmental time point. The mean and variance of each data set was calculated and the paired student t-test was performed at each time point with eight degrees of freedom. Significant differences (P50.001) between data sets are represented by asterisks. Bar in (b), 50 mm during lactation. Specifically, a dramatic reduction in b-casein expression levels was observed at 3 days postpartum (see Figure 4) . Previously reported in vitro and in vivo experimental systems corroborate a role for HRGa signaling in b-casein gene expression. HRG1 stimulated expression of b-casein in mammary gland organ cultures (Yang et al., 1995) and collagen cultures of EpH4 mammary epithelial cells (Niemann et al., 1998) . Furthermore, Elvax pellets containing HRGa induced b-casein expression and secretion when implanted within the mammary glands of nulliparous mice (Jones et al., 1996) .
Collaborative evidence suggests that HRG1 mammary gland signals may be mediated by the ErbB family members ErbB2 or ErbB4 or both. Similar to results presented here, inhibition of ErbB2 signaling in the developing mouse mammary gland, through targeted expression of a dominant negative mutant of ErbB2 (ErbB2DIC), results in a failure of lobuloalveolar functional maturation during pregnancy and reduced b-casein gene expression at parturition (F Jones, unpublished observations and Jones et al., 1999) . Likewise, impaired lobuloalveolar development and lactation defects were observed in mice lacking mammary gland expression of ErbB4 (W Long and F Jones, unpublished observations). Enhanced phosphorylated activation of ErbB family members within the developing mammary gland correlates with lobuloalveolar developmental abnormalities observed in HRGa-null mice during pregnancy and lactogenesis (Schroeder and Lee, 1998) . Despite the apparent correlation between HRGa, ErbB2, and ErbB4 activities during lobuloalveolar development and lactation, Western blot analysis of ErbB activation in HRGa-null pregnant and lactating mammary gland lysates failed to consistently identify an ErbB receptor regulated by HRGa (data not shown). These results suggest that a mechanism exists whereby the activities of HRGa are compensated for by overlapping expression of additional ErbB-regulating growth factors.
The intermittent disruption of lobuloalveolar development observed in HRGa-null mice during pregnancy and lactation may also be partially explained by functional compensation through the activities of other EGF family members. This premise is supported by an ambitious study where Luetteke et al. (1999) observed progressively severe alveolar phenotypes with accumulated deletions of AR, EGF, and TGFa alleles. Indeed, expression of these and other EGF family members overlaps with mammary expression of HRGa (Schroeder and Lee, 1998). Co-expression of multiple EGF ligands functioning during lobuloalveolar development and lactation may provide a compensatory mechanism that contributes to the mutational resiliency of the mammary gland. Alternatively, the transient alveolar phenotype observed in HRGa-null mice may reflect a specialized role for HRGa activity during the two stages of lobuloalveolar functional development when epithelial proliferation predominates.
The role of HRG1 as a potent mammary epithelial mitogen is further supported by a correlation between HRG1 expression and aggressive breast cancer. Despite their benign phenotype, stromal elements expressing HRG1 are juxtaposed to epithelial breast neoplasias and associated with poor prognosis (Visscher et al., 1997) . Similar to the putative function of HRGa as a paracrine mitogenic factor in the normal breast, these results suggest that HRG1 expressed in the stroma augments epithelial proliferation and contributes to breast carcinogenesis. In addition, overexpression of HRG1 as a transgene in a mouse model of breast cancer results in mammary epithelial tumors in multiparous mice (Krane and Leder, 1996) . The extracellular domain of HRG1, containing the EGF-homology domain, was sufficient to induce mammary tumors in a similar transgenic model (Weinstein et al., 1998) .
The experiments presented in this communication reveal an important role for HRGa in mammary epithelial proliferation and lobuloalveolar development during late pregnancy and early post-partum. In addition, HRGa-null mice exhibit severely impaired b-casein expression. Identification and functional analysis of cellular signals and transcriptional targets regulating the mitogenic activity of HRGa deserves further investigation. A thorough understanding of HRGa signaling pathways in the normal breast may provide crucial information for deciphering how aberrant HRGa activity contributes to aggressive breast cancer.
Materials and methods
Generation of HRGa-null mice
The EGF-like domains of HRG1 are encoded by exons 6, 7, and 8 ( Figure 1a) . The N-terminal portion of the EGF-like domain is encoded by exon 6 and present in both the a-and b-isoforms. The alternatively spliced exons 7 and 8 encode the a-and b-isoform-specific C-terminal portion of HRG1, respectively. To mutate the a-isoform, a targeting vector was constructed that contained a stop codon and novel EcoRI restriction site in exon 7 (Figue 1b), and, 5' of exon 7, a neo res cassette surrounded by loxP sequences that was used as a selection marker (Figure 1a) . In addition, a loxP site was introduced downstream of exons 8 and 9 (Figure 1a) . The presence of the desired sequence alterations in the targeting vector were verified by sequencing. ES cells were electroporated with the targeting vector shown in Figure 1 . The targeting vector was introduced into the genome of ES cells of the E14.1 line, that is derived from the 129/O1a strain, by homologous recombination (HRG1a neo), and the neo res cassette was removed by transient expression of Cre recombinase in ES cells (HRG1a). Homologous recombination events and the removal of the neo res cassette were monitored by Southern hybridization (Figure 1c , see also Figure 1a for the probes used). To verify the homologous recombination event, additional Southern hybridization experiments were performed with a genomic HRG1 probe that maps 3' to the sequences present in the targeting vector. The novel EcoRI restriction site present in exon 7 was particularly useful to identify the mutant allele. The two loxP sites that remain in the HRG1 gene after the removal of the neo res cassette allow the future use of the allele for a cell or tissue type-specific conditional mutation of HRG1. Two independently mutated ES cell colonies were used to establish strains that carry the HRGa mutation. The phenotype of HRGa-null mice was analysed on a mixed genetic background (129/Ola and C57/B16 and FVB).
Identification of HRGa-null mice by polymerase chain reaction (PCR)
Mice containing a genomic insertion at HRGa loci were identified by PCR analysis of DNA isolated from tail biopsies. DNA purification, PCR conditions, and controls have been described previously . PCR primers for the identification of wild type and mutant alleles were 5'-TCCTTTTGTGTGTGTTAGCACCGG and 5'-GCACCAAGTGGTTGCGATTGTTGCT. Amplification of the wild type HRGa allele resulted in a ca 260 bp fragment whereas the mutant allele gave a ca 400 bp fragment using the same PCR primers. Primers for the amplification of a ca 500 bp mouse b-casein exon 7 fragment served as a PCR internal control .
Wholemount staining of mouse mammary glands
The entire number four inguinal mammary gland was excised, spread onto a glass microscope slide, fixed in acidic ethanol, and stained in carmine solution exactly as described previously (Jones et al., 1996) .
Tissue preparation for histological analysis
For hematoxylin and eosin staining, immunohistochemistry, and in situ hybridization, a portion of the number four inguinal mammary gland was spread onto a glass microscope slide and fixed in freshly prepared 4% paraformaldehyde in PBS (15 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 137 mM NaCl, 3 mM KCl, pH 7.2) overnight at 48C. The fixed tissue was embedded in paraffin and 6 mm sections were dried onto Snowcoat X-tra slides (Surgipath) using standard procedures.
In situ hybridization
In situ hybridization was performed on paraffin embedded number four inguinal mammary glands from female mice at 3 days post-partum. All reagents and procedures for in situ hybridization analysis of b-casein, WAP, and a-lactalbumin expression using [
35 S]UTP labeled riboprobes have been described in detail elsewhere .
RNA isolation and Northern blot analysis
For isolation of mammary gland RNA, 200 mg of tissue from the number four inguinal mammary gland was snapfrozen in liquid nitrogen and stored at 7808C until use. RNA was isolated from frozen tissue by TRIzol (Invitrogen) extraction according to the manufacturer's instructions. For Northern blot analysis, 10 mg of total RNA was denatured at 708C in MOPS buffer (20 mM 3-n-morpholinepropanesulfonic acid [pH 7.0], 5 mM sodium acetate, 5 mM EDTA) containing 6% formaldehyde and 50% deionized formamide, separated in a 1% agarose gel prepared in MOPS buffer and 6% formaldehyde, and transferred to a Hybond-XL nylon membrane (Amersham Biosciences) using standard procedures. RNA was coupled to the nylon membrane in a Stratalinker UV cross-linker (Stratagene). The probes for bcasein, WAP, a-lactalbumin, and GAPDH (generously provided by D Joseph Jerry) were labeled with [ 32 P]dCTP by random priming, hybridized to the membrane at 658C overnight, washed extensively at 658C, air-dried, and exposed to autoradiographic film.
Bromodeoxyuridine (BrdU) immunohistochemistry
Proliferating cells within the mouse mammary gland were identified in situ by injecting mice ip 2 h prior to sacrifice with 10 ml/g body weight of BrdU Cell Labeling Reagent (Amersham). The number four inguinal mammary glands were excised from sacrificed mice and processed for histological analysis as described above.
For immunohistochemical detection of BrdU labeled cells, sections were first pretreated to expose nuclear epitopes. Briefly, deparaffinized sections were treated with 1 mg/ml of buffered trypsin (Sigma) for 20 min at 378C. Endogenous peroxidase activity was inactivated by incubating the sections in 0.5% H 2 O 2 in PBS for 15 min at room temperature. The sections were incubated in 2 N HCl for 1 h at room temperature followed by two washes in 100 mM borate buffer, pH 8.5 for 5 min per wash. The sections were treated with 0.2% NP-40 for 30 min at room temperature. Between each treatment the sections were washed twice in PBS for 5 min per wash. The treated sections were incubated overnight at 48C with anti-BrdU-POD (Roche) diluted to 1 : 10 or 1 : 15 in 10% goat serum, washed in PBS three times for 15 min per wash, and incubated with DAB substrate (Vector Labs, Inc.) for 20 min. Immunostained sections were lightly counterstained in hematoxylin (Vector Labs, Inc.) according to the manufacturers instructions, dehydrated in 100% EtOH, cleared in xylene, and cover slipped with Permount (Fisher Scientific Co.). Mammary glands from mice injected with saline in place of BrdU Cell Labeling Reagent served as negative controls.
For statistical analysis, the percentage of BrdU-labeled nuclei within wild type and HRGa-null mammary glands was determined at 6 -7 weeks, 17 days post-coitus, and 3 days post-partum, by counting 1000 epithelial nuclei from five different control and experimental mice at each developmental time point. The mean and variance of each data set was calculated and the paired student t-test was performed at each time point with eight degrees of freedom.
